中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.019 seconds)

    TACI AS AN ANTI-TUMOR AGENT
    1.
    发明申请
    TACI AS AN ANTI-TUMOR AGENT 审中-公开
    TACI作为抗肿瘤剂

    公开(公告)号：US20150218247A1

    公开(公告)日：2015-08-06

    申请号：US14631217

    申请日：2015-02-25

    Applicant: BIOGEN IDEC MA INC. ,  TOPOTARGET SWITZERLAND SA

    Inventor： Christine Ambrose ,  Jeffrey Thompson ,  Paul Rennert ,  Pascal Schneider

    IPC: C07K14/705

    CPC classification number: C07K14/70578 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/30

    Abstract: A method of treating a mammal for a condition associated with undesired cell proliferation comprising administering to said mammal an effective amount of a TACI reagent, wherein said reagent extends mean survival time of said mammal by about 10% or more as compared to the absence of administering the TACI reagent.

    Abstract translation: 一种治疗哺乳动物与不期望的细胞增殖相关的病症的方法，包括向所述哺乳动物施用有效量的TACI试剂，其中所述试剂与所述哺乳动物的不存在施用相比，将所述哺乳动物的平均存活时间延长约10％或更多 TACI试剂。

    FUSION CONSTRUCTS CONTAINING ACTIVE SECTIONS OF TNF LIGANDS
    2.
    发明申请
    FUSION CONSTRUCTS CONTAINING ACTIVE SECTIONS OF TNF LIGANDS 审中-公开
    包含TNF配体的活性部分的融合构建体

    公开(公告)号：US20150098944A1

    公开(公告)日：2015-04-09

    申请号：US14521631

    申请日：2014-10-23

    Applicant: TOPOTARGET SWITZERLAND SA

    Inventor： Olivier Gaide ,  Pascal Schneider ,  Jurg Tschopp

    IPC: C07K16/28 ,  C07K14/705

    CPC classification number: A61K39/3955 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70578 ,  C07K16/2875 ,  C07K2317/52 ,  C07K2319/30

    Abstract: Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.

    Abstract translation: 公开了含有氨基酸序列的重组融合蛋白，其包含：（a）作为组分（A）的免疫球蛋白的Fc部分或部分Fc部分或组分（A）的功能变体; （b）TNF配体的细胞外部分或作为组分（B）的TNF配体的细胞外部分的部分序列或组分（B）的功能变体; 和（c）组分（A）和组分（B）之间的过渡区域，其含有接头。

    Pharmaceutical composition comprising EDA-1 Fusion Protein
    4.
    发明授权
    Pharmaceutical composition comprising EDA-1 Fusion Protein 有权
    包含EDA-1融合蛋白的药物组合物

    公开(公告)号：US08895003B2

    公开(公告)日：2014-11-25

    申请号：US13922897

    申请日：2013-06-20

    Applicant: Topotarget Switzerland SA

    Inventor： Olivier Gaide ,  Pascal Schneider ,  Jurg Tschopp

    IPC: A61K39/395 ,  C07K14/705 ,  A61K38/00

    CPC classification number: A61K39/3955 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70578 ,  C07K16/2875 ,  C07K2317/52 ,  C07K2319/30

    Abstract: Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.

    Abstract translation: 公开了含有氨基酸序列的重组融合蛋白，其包含：（a）作为组分（A）的免疫球蛋白的Fc部分或部分Fc部分或组分（A）的功能变体; （b）TNF配体的细胞外部分或作为组分（B）的TNF配体的细胞外部分的部分序列或组分（B）的功能变体; 和（c）组分（A）和组分（B）之间的过渡区域，其含有接头。

Patent Agency Ranking